OR WAIT null SECS
April 11, 2025
Article
VERVE-102 is targeting the reduction of LDL-C levels among individuals with hyperlipidemia and high lifetime cardiovascular risk.
April 10, 2025
Video
Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.
April 08, 2025
Our Q1 2025 recap for cardiology spotlights 6 regulatory updates, 5 key trial announcements, and top expert perspectives in cardiac care.
April 03, 2025
A recap of 10 clinical trials in cardiovascular care to know from the American College of Cardiology 2025 Scientific Sessions.
April 01, 2025
At ACC.25, Boer highlights treatment gaps in the US for lipid control in a high-risk ASCVD population.
March 31, 2025
At ACC.25, Robert S. Rosenson, MD, discusses the efficacy and safety of solbinsiran, an ANGPTL3 inhibitor, in a population with mixed dyslipidemia.
March 30, 2025
Steve Nissen, MD, discusses the phase 2 ALPACA trial and how it informs the potential of lepodisiran for lowering Lp(a).
Phase 2 data at ACC.25 provide further insight into the effects of lepodisiran on serum Lp(a) and other biomarkers of risk.
March 27, 2025
OAC-naive patients experienced a significantly smaller increase in stroke or systemic embolism with asundexian than apixaban.
First Procedure Performed at AHN Wexford Hospital, Demonstrating Network’s Ongoing Commitment to Bringing Complex Cardiovascular Care into the Community
